These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 28709394)
21. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126 [TBL] [Abstract][Full Text] [Related]
22. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019 [TBL] [Abstract][Full Text] [Related]
23. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639 [TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290 [TBL] [Abstract][Full Text] [Related]
25. Performance of a vancomycin dosage regimen developed for obese patients. Reynolds DC; Waite LH; Alexander DP; DeRyke CA Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026 [TBL] [Abstract][Full Text] [Related]
26. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam. Holsen MR; Meaney CJ; Hassinger AB; Fusco NM Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. Al Yami MS J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320 [TBL] [Abstract][Full Text] [Related]
31. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients. Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798 [TBL] [Abstract][Full Text] [Related]
32. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Meaney CJ; Hynicka LM; Tsoukleris MG Pharmacotherapy; 2014 Jul; 34(7):653-61. PubMed ID: 24700598 [TBL] [Abstract][Full Text] [Related]
33. High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients. Rosini JM; Davis JJ; Muenzer J; Levine BJ; Papas MA; Comer D; Arnold R Acad Emerg Med; 2016 Jun; 23(6):744-6. PubMed ID: 26850378 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of Treatment Courses When Vancomycin Is Given Every 8 Hours in Adult Patients. Brumer E; Dubrovskaya Y; Scipione MR; Aberle C; Rahimian J; Papadopoulos J J Pharm Pract; 2015 Dec; 28(6):511-7. PubMed ID: 25112304 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963 [TBL] [Abstract][Full Text] [Related]
36. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia. Fullmer A; McCue D; Feng C J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356 [TBL] [Abstract][Full Text] [Related]
37. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Horey A; Mergenhagen KA; Mattappallil A Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306 [TBL] [Abstract][Full Text] [Related]
38. Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations. Rutter WC; Burgess DS Pharmacotherapy; 2017 May; 37(5):593-598. PubMed ID: 28247443 [TBL] [Abstract][Full Text] [Related]